CommercialPrior AuthMedium impact
08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)
Independence Blue Cross·Neurology, Pediatrics, Family Medicine·Pharmacy
Effective date
Mar 23, 2026
We identified it
Jun 19, 2026
Summary
The policy updates medical necessity criteria for two spinal muscular atrophy therapies: Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®). This affects prior authorization requirements and coverage criteria for these high-cost specialty medications used to treat spinal muscular atrophy.
Action Required
Before March 23, 2026: Clinical staff must review updated medical necessity criteria for Spinraza® and Zolgensma® therapies. Update prior authorization workflows and documentation requirements for spinal muscular atrophy treatments. Ensure providers understand new coverage criteria to avoid claim denials for these high-cost specialty medications.